Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism and Excretion of [14C] Anlotinib in Advanced Cancer
NCT02622932Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Cumulative excretion of 14C-labeled Anlotinib (radioactivity in urine) up to 10 Days, Cumulative excretion of 14C-labeled Anlotinib (radioactivity in feces) up to 10 Days and 7 more. Started Dec 2015; status: completed.
02
Drugs
anlotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02622932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622932.